7
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Multisystem inflammatory syndrome with particular cutaneous lesions related to COVID 19 in a young adult

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor: A previously healthy 21-year-old Caucasian man was admitted for vasoplegic shock. He denied any drug intake, did not smoke tobacco or use illicit drugs. He presented fever (39°C) with chest tightness, non-bloody watery diarrhea lasting for 7 days and a rash that had developed for 3 days. On clinical examination, he was febrile (40°C), blood pressure was 80/40 mm Hg, respiratory rate 38/mn, and oxygen saturation 97% in ambient air. An asymptomatic rash was present over the trunk and palms, consisting of erythematous round-shapped macules with a darker and raised rim, 1-3 cm in diameter, along with bilateral conjunctivitis (Figure 1 ). The white cell count was 16,000/mm3, with lymphocytes of 900/mm3. C-reactive protein level was of 365 mg/L, procalcitonine 3.4 ng/ml, ferritin 1,282 µg/l (normal<30), lactate 2.4 mmol/l (normal<1.6). Renal and liver function tests were within normal range, troponin level was 550 ng/l (normal<34). Cutaneous biopsy showed a slightly inflammatory infiltrate in upper dermis and direct cutaneous immunofluorescence was negative. Reverse transcription–polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 was negative on nasopharyngeal swab, saliva, stool specimen, and skin biopsy. Extensive infectious enquiry and search for antinuclear antibodies were negative. Electrocardiogram showed diffuse negative T waves, echocardiography displayed hyperkinetic left ventricle with normal ejection fraction, normal right cavities, and dilated noncompressible inferior vena cava. Thoraco-abdominal CT scan did not demonstrate pulmonary embolism or lung infection, but signs of congestive heart failure with bilateral pleural effusion, and wall thickening of the right colon with normal rectosigmoidoscopy. Treatment with volume resuscitation, noradrenaline and antibiotics (ceftriaxone and amikacin), then high flow nasal oxygenation because of respiratory function deterioration. Progressive clinical and biological features normalization, and the patient left the intensive care unit at day 8, while COVID-19 serology returned highly positive with IgG (ELISA SARS-CoV-2 Ig G Euroimmun). At four-weeks follow up he was healthy, heart CT scan and cardiac magnetic resonance imaging were normal with no sign of myocarditis or coronary aneurysms. Figure 1 Annular lesions over the trunk Figure 1 We report here a young adult multisystem inflammatory syndrome (MIS) due to COVID-19 virus who presented with vasoplegic shock and rash. Indeed, severe forms of COVID-19 infections affect mainly old people with underlying conditions. However, severe and systemic infections have been recently reported in children and teenagers close to atypical Kawasaki disease or toxic shock syndrome.1, 2, 3 This syndrome was described initially and termed MIS by Riphagen, 2 in a series of 8 children and teenagers with vasoplegic shock who experienced fever (8/8), rash (4/8), conjunctivitis (4/8), and gastrointestinal symptoms such as non-bloody diarrhea, vomiting and abdominal pain (7/8). None had significant respiratory involvement. One patient had a giant coronary aneurysm, another one died from cerebrovascular infarct. Diagnosis of covid-19 infection relied on RT-PCR testing on bronchoalveolar lavage or nasopharyngeal aspirate (2/8) and serology (8/8). Early treatment with intravenous immunoglobulins was given to all patients, and then 6 of them received aspirin. All children were discharged from the intensive care unit within 4-6 days. Preliminary diagnostic criteria have been subsequently proposed by the WHO in patients under 19 years old. 3 Our patient fulfilled the WHO diagnostic criteria of MIS. However, diagnosis of SARS-CoV2 was established late on the detection of serum SARS-CoV-2 antibodies and therefore no specific treatment was given. Cutaneous lesions associated with COVID-19 are present in up to 20% of patients including maculopapular rash, urticarial lesions, petechiae, and chilblains-like lesions. 4 The annular rash in our patient was particular and diagnosis of erythema multiforma and subacute lupus erythematosus were easily ruled out.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Hyperinflammatory shock in children during COVID-19 pandemic

          South Thames Retrieval Service in London, UK, provides paediatric intensive care support and retrieval to 2 million children in South East England. During a period of 10 days in mid-April, 2020, we noted an unprecedented cluster of eight children with hyperinflammatory shock, showing features similar to atypical Kawasaki disease, Kawasaki disease shock syndrome, 1 or toxic shock syndrome (typical number is one or two children per week). This case cluster formed the basis of a national alert. All children were previously fit and well. Six of the children were of Afro-Caribbean descent, and five of the children were boys. All children except one were well above the 75th centile for weight. Four children had known family exposure to coronavirus disease 2019 (COVID-19). Demographics, clinical findings, imaging findings, treatment, and outcome for this cluster of eight children are shown in the table . Table Demographics, clinical findings, imaging findings, treatment, and outcome from PICU Age; weight; BMI; comorbidities Clinical presentation Organ support Pharmacological treatment Imaging results Laboratory results Microbiology results PICU length of stay; outcome Initial PICU referral Patient 1 (male, AfroCaribbean) 14 years; 95 kg; BMI 33 kg/m2; no comorbidities 4 days >40°C; 3 days non-bloody diarrhoea; abdominal pain; headache BP 80/40 mmHg; HR 120 beats/min; RR 40 breaths per min; work of breathing; SatO2 99% NCO2 MV, RRT, VA-ECMO Dopamine, noradrenaline, argipressin, adrenaline milrinone, hydroxicortisone, IVIG, ceftriaxone, clindamycin RV dysfunction/elevate RVSP; ileitis, GB oedema and dilated biliary tree, ascites, bilateral basal lung consolidations and diffuse nodules Ferritin 4220 μg/L; D-dimers 13·4 mg/L; troponin 675 ng/L; proBNP >35 000; CRP 556 mg/L; procalcitonin>100 μg/L; albumin 20 g/L; platelets 123 × 109 SARS-CoV-2 positive (post mortem) 6 days; demise (right MCA and ACA ischaemic infarction) Patient 2 (male, AfroCaribbean) 8 years; 30 kg; BMI 18 kg/m2; no comorbidities 5 days >39°C; non-bloody diarrhoea; abdominal pain; conjunctivitis; rash BP 81/37 mmHg; HR 165 beats/min; RR 40 breaths/min; SVIA MV Noradrenaline, adrenaline, IVIG, infliximab, methylprednisolone, ceftriaxone, clindamycin Mild biventricular dysfunction, severely dilated coronaries; ascites, pleural effusions Ferritin 277 μg/L; D-dimers 4·8 mg/L; troponin 25 ng/L; CRP 295 mg/L; procalcitonin 8·4 μg/L; albumin 18 g/L; platelets 61 × 109 SARS-CoV-2 negative; likely COVID-19 exposure from mother 4 days; alive Patient 3 (male, Middle-Eastern) 4 years; 18 kg; BMI 17 kg/m2; no comorbidities 4 days >39°C; diarrhoea and vomiting; abdominal pain; rash; conjunctivitis BP 90/30 mmHg; HR 170 beats/min; RR 35 breaths/min; SVIA MV Noradrenaline, adrenaline, IVIG ceftriaxone, clindamycin Ascites, pleural effusions Ferritin 574 μg/L; D-dimers 11·7 mg/L; tropinin 45 ng/L; CRP 322 mg/L; procalcitonin 10·3 μg/L; albumin 22 g/L; platelets 103 × 109 Adenovirus positive; HERV positive 4 days; alive Patient 4 (female, AfroCaribbean) 13 years; 64 kg; BMI 33 kg/m2; no comorbidities 5 days >39°C; non-bloody diarrhoea; abdominal pain; conjunctivitis BP 77/41 mmHg; HR 127 beats/min; RR 24 breaths/min; SVIA HFNC Noradrenaline, milrinone, IVIG, ceftriaxone, clindamycin Moderate-severe LV dysfunction; ascites Ferritin 631 μg/L; D-dimers 3·4 mg/L; troponin 250 ng/L; proBNP 13427 ng/L; CRP 307 mg/L; procalcitonin 12·1 μg/L; albumin 21 g/L; platelets 146 × 109 SARS-CoV-2 negative 5 days; alive Patient 5 (male, Asian) 6 years; 22 kg; BMI 14 kg/m2; autism, ADHD 4 days >39°C; odynophagia; rash; conjunctivitis BP 85/43 mmHg; HR 150 beats/min; RR 50 breaths/min; SVIA NIV Milrinone, IVIG, methylprednisolone, aspirin, ceftriaxone Dilated LV, AVVR, pericoronary hyperechogenicity Ferritin 550 μg/L; D-dimers 11·1 mg/L; troponin 47 ng/L; NT-proBNP 7004 ng/L; CRP 183 mg/L; albumin 24 g/L; platelets 165 × 109 SARS-CoV-2 positive; likely COVID-19 exposure from father 4 days; alive Patient 6 (female, AfroCaribbean) 6 years; 26 kg; BMI 15 kg/m2; no comorbidities 5 days >39°C; myalgia; 3 days diarrhoea and vomiting; conjunctivitis BP 77/46 mmHg; HR 120 beats/min; RR 40 breaths/min; SVIA NIV Dopamine, noradrenaline, milrinone, IVIG, methylprednisolone, aspirin, ceftriaxone, clindamycin Mild LV systolic impairment Ferritin 1023 μg/L; D-dimers 9·9 mg/L; troponin 45 ng/L; NT-proBNP 9376 ng/L; CRP mg/L 169; procalcitonin 11·6 μg/L; albumin 25 g/L; platelets 158 SARS-CoV-2 negative; confirmed COVID-19 exposure from grandfather 3 days; alive Patient 7 (male, AfroCaribbean 12 years; 50kg; BMI 20 kg/m2; alopecia areata, hayfever 4 days >39°C; 2 days diarrhoea and vomiting; abdominal pain; rash; odynophagia; headache BP 80/48 mmHg; HR 125 beats/min; RR 47 breaths/min; SatO2 98%; HFNC FiO2 0.35 MV Noradrenaline, adrenaline, milrinone, IVIG, methylprednisolone, heparin, ceftriaxone, clindamycin, metronidazole Severe biventricular impairment; ileitis, ascites, pleural effusions Ferritin 958 μg/L; D-dimer 24·5 mg/L; troponin 813 ng/L; NT-proBNP >35 000 ng/L; CRP 251 mg/L; procalcitonin 71·5 μg/L; albumin 24 g/L; platelets 273 × 109 SARS-CoV-2 negative 4 days; alive Patient 8 (female, AfroCaribbean) 8 years; 50 kg; BMI 25 kg/m2; no comorbidities 4 days >39°C; odynophagia; 2 days diarrhoea and vomiting; abdominal pain BP 82/41 mmHg; HR 130 beats/min; RR 35 breaths/min; SatO2 97% NCO2 MV Dopamine, noradrenaline, milrinone, IVIG, aspirin, ceftriaxone, clindamycin Moderate LV dysfunction Ferritin 460 μg/L; D-dimers 4·3 mg/L; troponin 120 ng/L; CRP 347 mg/L; procalcitonin 7·42 μg/L; albumin 22 g/L; platelets 296 × 109 SARS-CoV-2 negative; likely COVID-19 exposure from parent 7 days; alive ACA= anterior cerebral artery. ADHD=attention deficit hyperactivity disorder. AVR=atrioventricular valve regurgitation. BMI=body mass index. BP=blood pressure. COVID-19=coronavirus disease 2019. CRP=C-reactive protein. FiO2=fraction of inspired oxygen. HERV=human endogenous retrovirus. HFNC=high-flow nasal canula. HR=heart rate. IVIG=human intravenous immunoglobulin. LV=left ventricle. MCA=middle cerebral artery. MV=mechanical ventilation via endotracheal tube. NIV=non-invasive ventilation. PICU=paediatric intensive care unit. RA=room air. RR=respiratory rate. RRT=renal replacement therapy. RV=right ventricle. RVSP=right ventricular systolic pressure. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. SatO2=oxygen saturation. SVIA=self-ventilating in air. VA-ECMO=veno-arterial extracorporeal membrane oxygenation. Clinical presentations were similar, with unrelenting fever (38–40°C), variable rash, conjunctivitis, peripheral oedema, and generalised extremity pain with significant gastrointestinal symptoms. All progressed to warm, vasoplegic shock, refractory to volume resuscitation and eventually requiring noradrenaline and milrinone for haemodynamic support. Most of the children had no significant respiratory involvement, although seven of the children required mechanical ventilation for cardiovascular stabilisation. Other notable features (besides persistent fever and rash) included development of small pleural, pericardial, and ascitic effusions, suggestive of a diffuse inflammatory process. All children tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on broncho-alveolar lavage or nasopharyngeal aspirates. Despite being critically unwell, with laboratory evidence of infection or inflammation 3 including elevated concentrations of C-reactive protein, procalcitonin, ferritin, triglycerides, and D-dimers, no pathological organism was identified in seven of the children. Adenovirus and enterovirus were isolated in one child. Baseline electrocardiograms were non-specific; however, a common echocardiographic finding was echo-bright coronary vessels (appendix), which progressed to giant coronary aneurysm in one patient within a week of discharge from paediatric intensive care (appendix). One child developed arrhythmia with refractory shock, requiring extracorporeal life support, and died from a large cerebrovascular infarct. The myocardial involvement 2 in this syndrome is evidenced by very elevated cardiac enzymes during the course of illness. All children were given intravenous immunoglobulin (2 g/kg) in the first 24 h, and antibiotic cover including ceftriaxone and clindamycin. Subsequently, six children have been given 50 mg/kg aspirin. All of the children were discharged from PICU after 4–6 days. Since discharge, two of the children have tested positive for SARS-CoV-2 (including the child who died, in whom SARS-CoV-2 was detected post mortem). All children are receiving ongoing surveillance for coronary abnormalities. We suggest that this clinical picture represents a new phenomenon affecting previously asymptomatic children with SARS-CoV-2 infection manifesting as a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome. The multifaceted nature of the disease course underlines the need for multispecialty input (intensive care, cardiology, infectious diseases, immunology, and rheumatology). The intention of this Correspondence is to bring this subset of children to the attention of the wider paediatric community and to optimise early recognition and management. As this Correspondence goes to press, 1 week after the initial submission, the Evelina London Children's Hospital paediatric intensive care unit has managed more than 20 children with similar clinical presentation, the first ten of whom tested positive for antibody (including the original eight children in the cohort described above).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Multisystem inflammatory syndrome in children and adolescents with COVID-19

              (2020)
                Bookmark

                Author and article information

                Contributors
                Journal
                Am J Med
                Am. J. Med
                The American Journal of Medicine
                Published by Elsevier Inc.
                0002-9343
                1555-7162
                23 July 2020
                23 July 2020
                Affiliations
                [a ]Unité de dermatologie, Hôpital René Dubos, Pontoise, France
                [b ]Service de réanimation, Hôpital René Dubos, Pontoise, France
                [c ]Unité d'infectiologie, Hôpital René Dubos, Pontoise, France
                [d ]Laboratoire de microbiologie, Hôpital René Dubos, Pontoise, France
                [e ]Service de cardiologie, Hôpital René Dubos, Pontoise, France
                [f ]Service de médecine interne, Hôpital Tenon (AP-HP), Paris, France
                Author notes
                [* ]Correspondence: Claude Bachmeyer, MD, Service de médecine interne, Hôpital Tenon (AP-HP), 4 rue de la Chine, 75020 Paris, France claude.bachmeyer@ 123456tnn.aphp.fr
                Article
                S0002-9343(20)30608-2
                10.1016/j.amjmed.2020.06.025
                7376358
                32712145
                14d07f70-ed71-4707-8ca6-3b0e1213f7e9
                © 2020 Published by Elsevier Inc.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Comments

                Comment on this article